Enoxoparin Sodium Injection ( Low Molecular Weight Heparin )

It binds to the fibrin of fresh clots and the resulting compound converts adjacent plasminogen into

There are many people that suffer from venous thromboembolism. Venous thromboembolism includes both deep vein thrombosis and pulmonary embolism. This is the third most common cause of vascular death after a myocardial infarction, also known as a heart attack, and stroke. This article examines the possibility of either full or low intensity anticoagulation therapy versus aspirin. This was a randomized study that consisted of 3,396 individuals who have venous thromboembolism. These individuals either received rivaroxaban, which is an anticoagulant, or 100 mg of aspirin once a day. The individuals in this study completed 6-12 months of anticoagulation therapy and were eligible for inclusion in the study if they were 18 years of age or older. The

Enoxaparin is a low molecular weight heparin used to prevent thrombosis, particularly post surgery. Enoxaparin binds to antithrombin III which is responsible for inhibiting coagulation by acting on factor Xa. Enoxaparin accelerates the activity of antithrombin III therefore preventing clot formation (McKenna & Lim, 2014 p766). When a blood vessel is damaged, platelets in circulating blood stick to the site of injury and release chemicals that attract more platelets causing aggregation. There are both intrinsic and extrinsic pathways causing thrombi to form to maintain a closed cardiovascular system (Hollar, 2017). Immobility increases risk of thrombus formation as the blood becomes stagnant with gravity and decreased

These TPAs are agents used to start hemostasis by converting plasminogen into plasmin, allowing fibrinolysis to occur (Alteplase). Hemostasis starts and it includes three processes combined that work together prevent or control blood loss (Alteplase). These three stages are vascular constriction, formation of the platelet plug and blood coagulation (Grossman, p.g.674). This means that Ronald is not a candidate for this medication since he is experiencing signs and symptoms of hemorrhagic stroke and this drug can make the bleed worsen due to clot dissolving mechanism. It is contraindicated to give a TPA to a patient experiencing an intracranial hemorrhage or active bleeding (Alteplase). Although he may not be able to have a TPA, he would be able to have medications that will try to help decrease his blood pressure and brain

Atrial fibrillation is the most frequent cardiac arrhythmia. There has always associated risk of clot formation and embolization that can lead to ischemic stroke. A large number of these ischemic events could be prevented by timely anticoagulation. Warfarin has been used for decades for this purpose, but there are many problems for the patients due to warfarin therapy like there is continuous need of INR monitoring, many food and drug interactions of the drug, late onset of action and risk of major bleeding. Anticoagulation with the Novel oral anticoagulants e.g. Dabigatran, rivaroxaban, apixaban, endoxaban led to similar or even lower rates of ischemic stroke and major bleeding compared to an adjusted dose of warfarin (INR 2-3) in patients

Anticoagulant therapy will started according to facility protocol. This therapy will decrease the blood’s ability to clot, and help to prevent the formation of new clots. Anticoagulants used will be warfarin, heparin, or coumadin. In facility therapy will be initiated via IV push according to facility protocol, with continuous monitoring of patient condition.

Andexanet appears to be an effective antidote for the reversal of factor Xa inhibitor anticoagulants.

It very important when giving an injection that there are no air bubbles in the needle. Its very important to make sure the substance you are injecting is getting in and not air. As a medical assistant I can make sure there are no bubbles by always drawing up my own injection.Making sure I always double check my syringe ,and if there are bubbles taking the proper procedures to remove the air bubbles. Its very important that your patient is getting all of their injection in the correct places and the correct

It inhibits thrombosis by inactivating co-factors Va, and VIIIa (Neyrinck, 2009). When deficient, Factor V can cause excessive blood clotting and Factor VIII, being an essential clotting factor, can cause blood to profusely move out of tissues once cut or damaged (Faust, 2001 and Yan, 2001). Thrombin may become limited, one reason being the decrease of plasma D-dimer, which again stimulates fibrinolysis (Bernard, 2001).

A: Potentiates the action of antithrombin III and thereby inactivates thrombin (as well as activated coagulation factors IX, X, XI, XII, and plasmin) and prevents the conversion of fibrinogen to fibrin; heparin also stimulates release of lipoprotein lipase (lipoprotein lipase hydrolyzes triglycerides to glycerol and free fatty acids)

Your medication Lovenox is the brand name for Enoxaparin, a blood thinning or anticoagulant drug, given to prevent and treat blood clots in a number of clinical situations, but primarily, like in your situation, to treat deep venous thrombosis or DVT. As you might not know, this drug is produced by chemically breaking down heparin (natural compound, which inhibits blood clotting) into smaller molecules, and it works by blocking the actions of Factor X and Factor II, which are two of the twelve clot-promoting proteins in blood.

Warfarin is a prescription medicinal drug used to save you harmful blood clots from forming or developing large. useful blood clots prevent or prevent bleeding, but dangerous blood clots can reason a stroke, coronary heart attack, deep vein thrombosis, or pulmonary embolism. because warfarin interferes with the formation of blood clots, it's far referred to as an anticoagulant. Many humans check with anticoagulants as “blood thinners”; but, warfarin does now not thin the blood but rather reasons the blood to take longer to form a clot. Warfarin decreases the body’s capability to form blood clots through blocking the formation of diet k–established clotting elements. diet okay is needed to make clotting elements and prevent bleeding. therefore,

In a hospital setting, anticoagulants and antiplatelets are widely prescribed by physicians because of their greater benefits in changing the physiological homeostasis of the cardiovascular system. Anticoagulants and antiplatelets play a fundamental role in the treatment of cardiovascular diseases as they are very effective at counteracting the different symptoms cardiovascular diseases present.

More patients are being started on factor Xa inhibitors due to their efficacy and safety profile compared to other agents, such as warfarin and enoxaparin. With the expanded use of these agents, there has come an increase in the occurrence of hospital admissions and deaths related to bleeding. It is estimated that in 2016, there were approximately 117,000 hospital admissions for bleeding caused by factor Xa inhibitors.1 Additionally, there were about 2,000 bleeding- related deaths per months.1 Up until May 2018, there was not an agent to reverse the effects of factor Xa inhibtors. In early May, the Food and Drug Administration (FDA) approved Andexxa, andexanet alfa, for the reversal of rivaroxaban and apixaban in the setting of life-threatening or uncontrolled bleeding.1

Adverse effects: Spontaneous bleeding, easily bruising, pain, redness, irritation at the site of injection, itching of the feet.